König, Christina http://orcid.org/0000-0002-3354-3496
Göpfert, Melanie
Kluge, Stefan http://orcid.org/0000-0001-8391-3988
Wichmann, Dominic http://orcid.org/0000-0002-4334-7640
Clinical trials referenced in this document:
Documents that mention this clinical trial
Posaconazole exposure in critically ill ICU patients: a need for action
https://doi.org/10.1007/s15010-023-02078-9
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 13 January 2023
Accepted: 16 July 2023
First Online: 27 July 2023
Declarations
:
: CK reports lecture fees from AMEOS, Gilead and Shionogi. SK received research support from Cytosorbents and Daiichi Sankyo. He also received lecture fees from ADVITOS, Biotest, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer and Zoll. He received consultant fees from Fresenius, Gilead, MSD and Pfizer. DW reports personal consultant and lecture fees from 3 M, Advants, AMEOS, Eumedica, EUSA, Gilead, Kite, Lilly, MSD, Novartis, Pfizer and Shionogi. MG reports no conflict of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Hamburg Chamber of Physicians (Ref.: PV7263).
: Informed consent was obtained from all subjects involved in the study either by the subjects itself or their legal representative.